Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHEC-66 is a standardized cannabis extract primarily being developed for the treatment of melanoma. It exerts its anti-tumor effects by inhibiting the viability of various melanoma cell lines, including MM418-C1, MM329, C32, and D24, through the induction of apoptosis and modulation of cell survival pathways. Research has demonstrated that PHEC-66 can have nuanced interactions with conventional chemotherapy; it shows potential additive effects when combined with auranofin or docetaxel, but may exhibit antagonistic effects when paired with cisplatin. The extract's mechanism of action is thought to involve the endocannabinoid system and the regulation of DNA damage responses and intracellular signaling. It is currently in the preclinical stages of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PHEC-66.